A suggested vaccine formulation for the control of pneumococcal meningitis in Egypt.
Mortality rates of pneumococcal meningitis ranges from 13-60% in different parts of the world. Reports of pneumococci with multiple antibiotic resistance add urgency to the need for developing means of primary prevention. A 14-valent pneumococcal vaccine was licensed in 1977, and a 23-valent pneumococcal vaccine in 1983. In the present work 131 strains of pneumococci isolated from meningitis cases in Egypt were identified and serotyped by Quellung reaction. The most frequently isolated serotype was serotype 1 (32%). Serotypes 6A, 9L, 12A, 19A and 29 were next in prevalence. The age groups 0-18 years were the most frequently affected groups (79%) and over 18 years of age were only 21% of total cases. A vaccine formulation is suggested to have a coverage rate against pneumococcal meningitis cases of 79.3% and 89.3% of a proposed 14-valent vaccine and 23-valent vaccine versus to coverage rate of 48% and 54% of 14-valent and 23-valent International vaccines respectively. According to the age distribution of cases and the isolated serotypes a vaccination could be recommended during the first two years of age in order to protect the most frequently infected groups.